{"name":"Sangamo Therapeutics","slug":"sangamo-therapeutics","ticker":"","exchange":"","domain":"","description":"Sangamo Therapeutics, Inc. is an American biotechnology company based in Brisbane, California, that develops cell and gene therapies for severe genetic diseases.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":36567000,"revenueGrowth":179.6,"grossMargin":0,"rdSpend":111521000,"netIncome":-97941000,"cash":101635000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2017"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"TX200-TR101","genericName":"TX200-TR101","slug":"tx200-tr101","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"TX200-TR101","genericName":"TX200-TR101","slug":"tx200-tr101","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"date":"2026-03-30","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-04","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE9wWGc1YVkxQkhfR3MwQk43NnJsY2tVOUlwYVFpaWNMVWVGcUhacTFpdnlOTWQzczY2bzlMWXo2eHpGQ25sYWJVVkFLMmtBaHFkVDBZ?oc=5","date":"2025-11-21","type":"regulatory","source":"FirstWord Pharma","summary":"Sangamo plans earlier filing of Fabry gene therapy after FDA meeting - FirstWord Pharma","headline":"Sangamo plans earlier filing of Fabry gene therapy after FDA meeting","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxQZmpmd1lwQWZuSE0wQ0FOanYxQml6TkJ6TmEzUnZJZFdfc2NBZlc4R0dSR01mM1Z2TXFUem01ZzZKNWItbkVsc2RDU1FpcXJPMWxDRktoZU4xNV9vMmR6bnRwZktLd1hqWVk1NWZERGo0NDRDQUlreW03ZXJLQWxjTHVoX19LUUZJNFpFSVFB?oc=5","date":"2025-09-24","type":"pipeline","source":"Medical Marketing and Media","summary":"The Escalator: Zealand Pharma, Area 23, Sangamo Therapeutics and more - MM+M - Medical Marketing and Media","headline":"The Escalator: Zealand Pharma, Area 23, Sangamo Therapeutics and more - MM+M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxPcEhaRnhTTkJ5TTY5ZmNGNFNYdERleE40aUN3SWJZVnQyVGRneW44ZTdZazBUZDZzbGkyOXVvTGFIZDZreEJiZUtKX0VRbXRlQXJFSW40by1zcUNFNGpfZEdzTHFqZXdSN05ULXdPWmlacHcxY0o5ZE9hWXd1T1hveg?oc=5","date":"2025-09-18","type":"deal","source":"statnews.com","summary":"Sangamo's Fabry therapy partner search looks futile, and Geoff Porges is back - statnews.com","headline":"Sangamo's Fabry therapy partner search looks futile, and Geoff Porges is back","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxNNzV4emJ5VXQ5WTJOYzdtQVp2WU44aEk0c1JKc3hKT2hQSXRfcVR6THJ6SUJFQUlJeDJjUnlwWnBsVXpDeUgySmNmaklFZ0pjYTRVQ0tDX0pEeU1ZSmozeG9NcGZlWm1MOVRfbUVPOWpJT1ptd0NQXy1FV2NBWGU5aVd5SlRvQQ?oc=5","date":"2025-06-25","type":"trial","source":"pharmaphorum","summary":"Sangamo cues up Fabry gene therapy filing on STAAR data - pharmaphorum","headline":"Sangamo cues up Fabry gene therapy filing on STAAR data","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQRXF4VXI5RXV4MHFxbXN6YzYxQy1pQ3BIWEFrY2dyWWtVSGxPYmY0dWlJbEJyT3JOSkR0b0M3ZU85VVcxWjN2NWpKSjVIZjJDc2xvYzNuZzJOV1NqRjZRVE16NVhQNWVBOHN5OS02Y2VzNXpUWW1LbHg2cFdDbnVlQU1nZGE4S19wdl9RLTU1VkoxX2FzdFpWb1VtVnY?oc=5","date":"2025-04-04","type":"pipeline","source":"BioSpace","summary":"Lilly Throws Sangamo a Lifeline With Pact Worth Potential $1.4B+ - BioSpace","headline":"Lilly Throws Sangamo a Lifeline With Pact Worth Potential $1.4B+","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxNMmZRdmxfMGhhTDZtak04cVlSUVhvcWw0MU1IcC10b09kcnNsQlA5QXJ6eWY0UjRYanhhbDdOaDY2dElWTUNuOFNUSXk1Z2hHMUhhVjZ4OWd6c2hHNTVCTm9IM3Voa2dEbS1KTHI5QmdXaVZxZWsyNVZoT0s5UG1FeTg2bw?oc=5","date":"2025-04-04","type":"deal","source":"The Pharma Letter","summary":"Sangamo Thera enters critical deal with Lilly - The Pharma Letter","headline":"Sangamo Thera enters critical deal with Lilly","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxNcDlxbVZSX2hVTUVybzNkRzNiLUF5YlhZaXhQUW9Kc091MHRWNm01UUNtbVQycklqeV9xdUR4WHNKLUQ1VEtkZ08zT0hFQ0E1YXY3LVczTnRiN0tiWVNOUHlWbEluRERsS1ZfUU9TVnprRlctbE00eGJRODViX1BVci1vTU5ta1hVYUdRVngxZEdQWVlrdVo2UFBzT2wzREo2UFVKcA?oc=5","date":"2025-04-03","type":"deal","source":"Fierce Biotech","summary":"Eli Lilly helps struggling Sangamo with $1.4B gene therapy deal - Fierce Biotech","headline":"Eli Lilly helps struggling Sangamo with $1.4B gene therapy deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNcWpyME9pOUVpTnFrdWJJY0xLaThXNWk4d1kza3JPZmlibXIxeTFkNDFOWHliWDFfMDMyMDdNZjlmcXJQOUNxVkladUlkRGx5N1dTdjd0Y054bVlVUzlRaFVhczZFb20yWUpMMkFNWWhVVnpaakdwdEdoS2hzUjdwLWU1SnZxUWNpSE9J?oc=5","date":"2025-01-02","type":"deal","source":"Barron's","summary":"Sangamo Therapeutics Stock Plummets 56% After Pfizer Ends Hemophilia Treatment Partnership - Barron's","headline":"Sangamo Therapeutics Stock Plummets 56% After Pfizer Ends Hemophilia Treatment Partnership - Barron's","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPWlpSSU80SUUxMjFhaHFOVm5JYVhnaW5pUG1wc3lxMlA0Vm5sUjRqV3VDQW9CdjdCY3dpczVYcTNxWVpVeWVRSE9rYnE3QmNVTm93Y1RXeWJMaEpyb3RzUEdqLWVCdzEwcEQ3RDlCbDBrcHF0WDNYQ1ViQVVYM1lydmtoV1U2bGNmLUNSY0hRWlFxMF9rS1VOS2h2U3NtY3BQV3NQWGduQjhrbnRFOWZGMDJRWm9zaEtuRU04?oc=5","date":"2025-01-02","type":"pipeline","source":"Contract Pharma","summary":"Sangamo Therapeutics to Regain Rights to Gene Therapy Program from Pfizer - Contract Pharma","headline":"Sangamo Therapeutics to Regain Rights to Gene Therapy Program from Pfizer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxQNVF5ckJFS3JTd204SVJjay1Vb3hyZnd4R2pQR3RuTXFsaFlpOE5VQjNReEUtLWQzWXRzU3NaZmZWNmZ1cHBuSThtWC12UFlQTjBSV0M5RVZtWGR0dWZISUtCeVE1Nk1SRU9oLWhvb0pLek85cGNLaTVwUkU2QTdrZV9qZzl2QjMySTRaUw?oc=5","date":"2024-12-20","type":"deal","source":"Pharmaceutical Technology","summary":"Astellas and Sangamo sign capsid deal for neurological diseases - Pharmaceutical Technology","headline":"Astellas and Sangamo sign capsid deal for neurological diseases","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":36567000,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":36567000,"period":"2017-12-31"},{"value":13077000,"period":"2017-12-31"},{"value":11812000,"period":"2017-09-30"},{"value":8253000,"period":"2017-06-30"},{"value":3425000,"period":"2017-03-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":111521000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-97941000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":101635000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}